Exercise in Metastatic Breast Cancer: EMBody

Prior treatment

• Receiving cytotoxic chemotherapy at any point in the prior 12 months.
  • Participants receiving endocrine therapy are eligible.
  • Participants receiving targeted therapy or antibody therapy are eligible (examples including trastuzumab, pertuzumab, TDM-1, trastuzumab deruxtecan, sacituzumab govetecan, immunotherapy, CDK4/6 inhibitors, olaparib, alpelisib, etc.)
• Any condition precluding supervised exercise participation. A letter from a physician supporting participation can supersede this eligibility criteria.
  • NYHA class III or IV congestive heart failure
  • Uncontrolled angina
  • Myocardial infarction in the prior 12 months
  • Orthopedic surgery in the previous 3 months or plans for orthopedic surgery during the study period
  • Chronic uncontrolled pulmonary conditions such as uncontrolled asthma (symptoms \> 2 days/week) or dyspnea requiring oxygen
  • Symptomatic peripheral vascular disease
  • Or any other comorbidity that would interfere with the ability to complete and comply with the protocol in the opinion of the investigator, including psychological illness
  • History of fragility fracture

Other

• Active, untreated brain metastases

• Age ≥ 18 years
• Diagnosis of metastatic breast cancer
• No progression of disease in the 12 months prior to screening per the treating investigator
  • If participant has changed treatments in the prior 12 months for reasons other than progressive disease, they remain eligible
  • Participants on no treatment or "no evidence of disease" but still with a diagnosis of metastatic breast cancer are eligible
• ECOG performance status of 0-2
• Ability to walk on a treadmill without assistive device.
• Informed consent and authorization of the release of health information must be obtained according to institutional guidelines
• Currently not meeting physical activity guidelines (defined as less than 150 minutes of moderate to vigorous exercise per week measured by the IPAQ questionnaire administered during screening)
• Participants should have a cellular device compatible with iOS 15 or Android operating system 7.